Trial Profile
Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LONESTAR
- 18 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 18 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.
- 18 Oct 2023 Planned number of patients changed from 360 to 400.